A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction‐associated fatty liver disease
  di: Minji Lee, et al.
  Pubblicazione: (2024)
• Glutamate as a therapeutic strategy to promote liver regeneration
  di: María del Mar Rigual, et al.
  Pubblicazione: (2025)
• Intestinal Fut2 deficiency exacerbated alcohol‐related liver disease by disrupting nicotinamide metabolism
  di: Liuying Chen, et al.
  Pubblicazione: (2025)
• NLRP3 activation maintains intestinal epithelial barrier and reduces liver injury in alcoholic liver disease mice
  di: Shi‐Qing Li, et al.
  Pubblicazione: (2024)
• Comprehensive transcriptome, miRNA and kinome profiling identifies new treatment options for personalized lung cancer therapy
  di: Shen Zhong, et al.
  Pubblicazione: (2025)